Kristina Kaminskaya
Papers
2
Total Citations
4
H-Index
2
About
Kristina Kaminskaya is a leading researcher in the field of oral biologic drug delivery, with a focus on developing patient-friendly alternatives to injectable therapies. Her major contributions center on the proof-of-concept and pharmacokinetic/pharmacodynamic (PK/PD) evaluation of hormone analogs delivered via an innovative, orally ingestible robotic pill platform. Notably, she co-authored two highly cited 2023 studies: one demonstrating patient preference and proof-of-concept for a once-daily follicle stimulating hormone (FSH) biosimilar (RT-112), and another characterizing the PK/PD of the parathyroid hormone analog teriparatide (RT-102) for osteoporosis. These works, each garnering 2 citations, represent early but pivotal evidence that complex biologics can be effectively administered orally, potentially transforming treatment adherence for conditions requiring frequent injections. Kaminskaya’s research, conducted at Rani Therapeutics, bridges patient-centered design with rigorous preclinical validation, offering a glimpse into a future where robotic pills replace needles for chronic disease management. Her achievements underscore her role at the forefront of bioengineering and translational medicine.
Research Focus
Key Achievements
Top Papers
- 1
- 2